

- 【Therapeutic category】 429 Other antitumor agents
- 【Non-proprietary name】 Atezolizumab (genetical recombination)
- Avelumab (genetical recombination)
- Ipilimumab (genetical recombination)
- Cemiplimab (genetical recombination)
- Tislelizumab (genetical recombination)
- Durvalumab (genetical recombination)
- Tremelimumab (genetical recombination)
- Nivolumab (genetical recombination)
- Retifanlimab (genetical recombination)
- 【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Vasculitis</u> <u>Large-vessel vasculitis, medium-vessel vasculitis, or small-vessel vasculitis</u> <u>[including anti-neutrophil cytoplasmic antibody (ANCA)-associated</u> <u>vasculitis, IgA vasculitis, and cutaneous vasculitis] may occur.</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.